TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34796395
Drug: Increased parent
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased parent and self-identification of medication barriers (per 1 point)
Study: 34797221
Drug: 20% albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% albumin administered at 3 mL/kg by intravenous infusion over 30 minutes
Study: 34797307
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test in FM patients
Study: 34799399
Drug: NIZ985 (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIZ985 (0.25, 0.5, 1, 2 or 4 µg/kg subcutaneous TIW for the first 2 weeks of each 28-day cycle)
Study: 34800109
Drug: Isatuximab in
Normalized name: isatuximab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isatuximab in combination with pomalidomide plus dexamethasone
Study: 34800167
Drug: Myasthenia gravis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myasthenia gravis patients (MG)
Study: 34800279
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) for cardioembolic LVO (CE-LVO)
Study: 34800279
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) for other stroke subtypes
Study: 34800495
Drug: Photobiomodulation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation Therapy (FBMT)
Study: 34800678
Drug: Vibostolimab monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibostolimab monotherapy (2.1-700 mg)
Study: 34800678
Drug: Vibostolimab plus
Normalized name: Vibostolimab
DrugBank: Vibostolimab (DB16420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibostolimab plus pembrolizumab (200 mg) combination therapy
Study: 34800678
Drug: Vibostolimab plus
Normalized name: Vibostolimab
DrugBank: Vibostolimab (DB16420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibostolimab plus pembrolizumab combination therapy in anti-PD-1/PD-L1-naive NSCLC
Study: 34800678
Drug: Vibostolimab monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibostolimab monotherapy in anti-PD-1/PD-L1-refractory NSCLC
Study: 34800678
Drug: Vibostolimab plus
Normalized name: Vibostolimab
DrugBank: Vibostolimab (DB16420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibostolimab plus pembrolizumab combination therapy in anti-PD-1/PD-L1-refractory NSCLC
Study: 34800988
Drug: Postoperative physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative physical therapy
Study: 34801015
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (calcium and active vitamin D)
Study: 34801051
Drug: Weifuchun (WFC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weifuchun (WFC) tablets, 1.44 g three times a day for 6 months
Study: 34801051
Drug: Vitacoenzyme (Vit)
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitacoenzyme (Vit) tablets, 0.8 g three times a day for 6 months
Study: 34801051
Drug: WFC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: WFC treatment
Study: 34801354
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg Q3W plus trametinib 1.5 mg QD (concurrent DL2a)
Study: 34801354
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg Q3W plus trametinib 2 mg QD (intermittent DL2)
Study: 34801354
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg Q3W plus trametinib 1.5 mg QD (concurrent DL1)
Study: 34801354
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg Q3W plus trametinib 1.5 mg QD (concurrent DL2b)
Study: 34801354
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg Q3W plus trametinib 2 mg QD (intermittent DL1)
Study: 34801735
Drug: ECG patch
Normalized name: Ecgonine
DrugBank: Ecgonine (DB01525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECG patch monitoring pre-, immediately post-, and 2-3 months post-TAVR
Study: 34801735
Drug: ECG patch
Normalized name: Ecgonine
DrugBank: Ecgonine (DB01525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECG patch monitoring
Study: 34801749
Drug: Aumolertinib (110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aumolertinib (110 mg orally once daily)
Study: 34802427
Drug: Flexible and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible and integrated treatment (FIT) model project at the model hospital
Study: 34802455
Drug: Permethrin-treated uniform
Normalized name: Permethrin
DrugBank: Permethrin (DB04930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Permethrin-treated uniform with placebo lotion
Study: 34802455
Drug: Untreated uniforms
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Untreated uniforms with placebo lotion
Study: 34802792
Drug: BNT162b2 mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 mRNA COVID-19 vaccine (first dose)
Study: 34802792
Drug: BNT162b2 mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 mRNA COVID-19 vaccine (second dose)
Study: 34802864
Drug: Nivolumab 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 360 mg and docetaxel 75 mg/m²
Study: 34802966
Drug: Cabozantinib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (60 mg initiated, average dose 45.5 mg/day)
Study: 34802966
Drug: Cabozantinib (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (treatment line subgroups)
Study: 34803851
Drug: Enhancing left
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhancing left beta/theta power ratio NF training in combination with reducing right beta/theta power ratio NF training
Study: 34804358
Drug: Oral doxycycline
Normalized name: doxycycline Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doxycycline 100mg once daily
Study: 34804608
Drug: Metformin-inclusive sulfonylurea
Normalized name: metformin and sulfonylureas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin-inclusive sulfonylurea
Study: 34804608
Drug: Sulphonylurea(s) monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphonylurea(s) monotherapy
Study: 34804848
Drug: Temsirolimus 25
Normalized name: temsirolimus 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus 25 mg weekly
Study: 34805632
Drug: AZD5718 (5-Lipoxygenase
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5718 (5-Lipoxygenase Activating Protein Inhibitor)
Study: 34805632
Drug: AZD5718 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5718 plus dapagliflozin (10 mg/d)
Study: 34805723
Drug: Whole-grain diet
Normalized name: rice (whole grain) allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-grain diet (50 g/1000 kcal per day)
Study: 34806137
Drug: Dupilumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab plus topical corticosteroids (TCS)
Study: 34806163
Drug: GELAD chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GELAD chemotherapy regimen (gemcitabine 1.0 g/m²)
Study: 34808524
Drug: Combinations of
Normalized name: Combinations of vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combinations of six molecularly targeted agents and a PD-L1 antagonist
Study: 34808624
Drug: rhythmic speech-language
Normalized name: TRACH TUBE,SPEECH SZ 10 BLOM #313-30-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhythmic speech-language therapy (rSLT)
Study: 34808624
Drug: no-therapy (NT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: no-therapy (NT)
Study: 34809507
Drug: Apixaban discontinuation
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban discontinuation prior to surgery
Study: 34809974
Drug: Total folate
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Total folate intake up to 1,200 μg/d
Study: 34809974
Drug: Supplemental folate
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supplemental folate intake up to 800 μg/d
Study: 34812424
Drug: Sarilumab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab (400 mg intravenously on day 1 and on day 3 if clinically indicated)
Study: 34813486
Drug: VR treatment
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VR treatment (self-guided, mobile app-based VR CBT)
Study: 34813506
Drug: TIL infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TIL infusion products
Study: 34813910
Drug: Once-weekly exenatide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly exenatide (EQW) plus usual care
Study: 37639820
Drug: Oral targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral targeted therapy
Study: 34814935
Drug: Nafamostat mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafamostat mesilate (0.1 to 0.2 mg/kg/h, 2.4 to 4.8 mg/kg/day) with standard therapy
Study: 34814935
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (lopinavir/ritonavir, hydroxychloroquine, oxygen therapy, non-invasive and invasive ventilator, antibiotic therapy, renal-replacement therapy, ECMO)
Study: 34816294
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg methylprednisolone and 5 mg/day ruxolitinib
Study: 34817837
Drug: 2020 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2020 treatment of benign/precursors diseases
Study: 34817837
Drug: 2020 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2020 treatment of neuroendocrine tumors
Study: 34818478
Drug: Belzutifan (MK-6482)
Normalized name: belzutifan
DrugBank: Belzutifan (DB15463)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Belzutifan (MK-6482) 120 mg daily
Study: 34818965
Drug: Elotuzumab in
Normalized name: elotuzumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elotuzumab in combination with pomalidomide, carfilzomib, and low-dose dexamethasone
Study: 34818965
Drug: Elotuzumab in
Normalized name: elotuzumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elotuzumab in combination with pomalidomide, carfilzomide, and low-dose dexamethasone
Study: 34819039
Drug: Entinostat monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entinostat monotherapy (3 mg/qw, 5 mg/qw, or 10 mg/q2w)
Study: 34819039
Drug: Entinostat combined
Normalized name: entinostat
DrugBank: Entinostat (DB11841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entinostat combined with exemestane (5 mg/qw + 25 mg/qd)
Study: 34819039
Drug: Entinostat monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entinostat monotherapy and combined entinostat/exemestane
Study: 34819116
Drug: Osteopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic treatment in addition to treatment as usual (TAU) - 5 sessions of 30 minutes each, using soft specific palpatory techniques on the diaphragm, digestive system, and cervical region.
Study: 34819116
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) only.
Study: 34819138
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of autologous adipose tissue (AT) around the anal fistula tract
Study: 34820133
Drug: Cisplatin therapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin therapy
Study: 34822128
Drug: Physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's choice of treatment
Study: 34823566
Drug: Hearing implants
Normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hearing implants
Study: 34824054
Drug: Oral corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroid (OCS) use
Study: 34824109
Drug: Clinical pharmacists
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical pharmacists integrated into the ED team providing pharmaceutical care services such as medication reconciliation, review and/or counselling.
Study: 34824124
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 3 g of fosfomycin
Study: 34824124
Drug: 2 days of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 days of 3 g of fosfomycin o.d.
Study: 34824124
Drug: 3 days of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 days of pivmecillinam 400 mg three times per day (t.i.d)
Study: 34824124
Drug: 5 days of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of nitrofurantoin 100 mg t.i.d.
Study: 34824133
Drug: Perfusion-guided endovascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfusion-guided endovascular super-selective intra-arterial infusion of mesenchymal stem cells loaded with Delta-24 (MSC-D24)
Study: 34824133
Drug: Perfusion-guided endovascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfusion-guided endovascular super-selective intra-arterial infusion of MSC-D24
Study: 34824596
Drug: Janssen Ad26.COV2.S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Janssen Ad26.COV2.S vaccine
Study: 34825282
Drug: Neoadjuvant systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant systemic therapy (NST) for 12 weeks, combinatorial based on BRAF status.
Study: 34826114
Drug: SHP465 mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHP465 mixed amphetamine salts (MAS) 6.25 mg once daily for 28 days
Study: 34826122
Drug: FLECTOR (diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLECTOR (diclofenac epolamine topical system)
Study: 34826412
Drug: Pola-G-Len (polatuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pola-G-Len (polatuzumab vedotin 1.4 mg/kg + lenalidomide 20 mg + obinutuzumab 1000 mg)
Study: 34829796
Drug: PARP Inhibitors
Normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARP Inhibitors
Study: 34829967
Drug: Oral bacteriotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bacteriotherapy (Vivomixx® in EU, Visbiome® in USA) for 6 months
Study: 34831051
Drug: Lp(a) levels
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lp(a) levels <30 mg/dL
Study: 34831051
Drug: Lp(a) levels
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lp(a) levels ≥30 mg/dL
Study: 34831332
Drug: Mild prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild prolonged hypoglycemia (blood glucose maintained at 2.8 mmol/L for 1 hour)
Study: 34834511
Drug: Salmeterol/Fluticasone Fixed-Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/Fluticasone Fixed-Dose Combination (SFC) via Elpenhaler for 12 months
Study: 34835197
Drug: ERUCoV-VAC (whole-virion
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERUCoV-VAC (whole-virion inactivated SARS-CoV-2 vaccine candidate)
Study: 34836907
Drug: Brief Contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief Contact Interventions (BCIs) monthly
Study: 34836907
Drug: Brief Contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief Contact Interventions (BCIs) weekly
Study: 34836908
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) and high-intensity statins (atorvastatin or rosuvastatin) within 24 hours of stroke onset, followed by aspirin or clopidogrel alone from day 22.
Study: 34836908
Drug: Single antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single antiplatelet therapy without high-intensity statin treatment (historical control).
Study: 34837382
Drug: Roselle extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roselle extract capsules (total dose of 5600 mg)
Study: 34837553
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula (HFNC) therapy set at 40 L/min and titrated based on improvement in ROX index and patient tolerance.
Study: 34837553
Drug: HFNC flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFNC flow set at 45 L/min at enrollment.
Study: 34838114
Drug: S-ketamine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ketamine (0.2 mg/kg)
Study: 34838114
Drug: S-ketamine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ketamine (0.4 mg/kg)
Study: 34838114
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment without S-ketamine
Study: 34838125
Drug: Metacognitive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metacognitive therapy (MCT) and work-focused interventions
Study: 34838717
Drug: Oral HPV
Normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HPV prevalence measured using a commercially available PCR DNA test.
Study: 34839055
Drug: Home-based intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based intensive chemotherapy
Study: 34839199
Drug: EMI-137 (0.13
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMI-137 (0.13 mg/kg) administered intravenously 1-3 hours before surgery
Study: 34839196
Drug: Infant's medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant's medication number at hospital discharge
Study: 34839196
Drug: Medications number
Normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medications number at hospital discharge
Study: 34839425
Drug: Implant Reconstruction
Normalized name: CONSTRICTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant Reconstruction
Study: 34840651
Drug: Oral glutathione
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glutathione supplement (L-glutathione, ascorbic acid, alpha-lipoic acid, zinc as zinc aspartate)
Study: 34840720
Drug: Talazoparib (0.1-2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib (0.1-2.0 mg once daily)
Study: 34841093
Drug: PIRATES approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIRATES approach (intensity-modulated proton therapy, mid-treatment hybrid hyper-fractionation, MRI-guided mid-treatment boost volume adaptation, iso-effective restricted organ-at-risk dosing)
Study: 34842060
Drug: Virtual group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual group therapy intervention (8 sessions over 4 weeks)
Study: 34842546
Drug: Remote GDMT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote GDMT titration intervention
Study: 34842557
Drug: Iowa Gambling
Normalized name: influenza B virus B/Iowa/06/2017 antigen
DrugBank: Influenza B virus B/Iowa/06/2017 antigen (MDCK cell derived, propiolactone inactivated) (DB15508)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iowa Gambling Task administered via a web app
Study: 34843044
Drug: Sapanisertib (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sapanisertib (3 mg QD)
Study: 34843401
Drug: Poziotinib (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poziotinib (16 mg) once daily
Study: 34843469
Drug: Fractional-dose 17DD-YF
Normalized name: Poliovirus, inactivated, fractional-dose (fIPV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional-dose 17DD-YF vaccine in ARD patients
Study: 34843666
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with dexamethasone and anti-IL-6
Study: 34844283
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy guided by continuous glucose monitoring systems (CGMS)
Study: 34844283
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy guided by other forms of glucose data collection
Study: 34844422
Drug: Moderate hyperglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate hyperglycemia (serum glucose levels ≥140 mg/dL-<180)
Study: 34844422
Drug: Severe hyperglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe hyperglycemia (serum glucose levels ≥180 mg/dL)
Study: 34844770
Drug: Lanreotide Autogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide Autogel 120 mg (LAN 120 mg)
Study: 34844977
Drug: Etigilimab alone
Normalized name: Etigilimab
DrugBank: Etigilimab (DB18854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etigilimab alone (0.3, 1.0, 3.0, 10.0, 20.0 mg/kg intravenously)
Study: 34844977
Drug: Etigilimab in
Normalized name: Etigilimab
DrugBank: Etigilimab (DB18854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etigilimab in combination with nivolumab (3.0, 10.0, 20.0 mg/kg etigilimab and 240 mg nivolumab)
Study: 34844980
Drug: Anlotinib +
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib + PD-1 checkpoint inhibitor
Study: 34844993
Drug: Conventional Treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Treatments
Study: 34845071
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1,200 mg/m²
Study: 34845082
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of PCV10 at 24 months (Control group)
Study: 34845300
Drug: Ranibizumab intravitreal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab intravitreal injections in vitrectomized eyes
Study: 34845300
Drug: Ranibizumab intravitreal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab intravitreal injections in non-vitrectomized eyes